ProfileGDS4814 / ILMN_1815733
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 95% 96% 96% 96% 95% 95% 95% 96% 96% 96% 96% 96% 96% 96% 96% 97% 96% 96% 95% 97% 95% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)949.22395
GSM780708Untreated after 4 days (C2_1)1178.4296
GSM780709Untreated after 4 days (C3_1)1187.5396
GSM780719Untreated after 4 days (C1_2)1014.8896
GSM780720Untreated after 4 days (C2_2)925.64795
GSM780721Untreated after 4 days (C3_2)947.62895
GSM780710Trastuzumab treated after 4 days (T1_1)960.45395
GSM780711Trastuzumab treated after 4 days (T2_1)1170.0396
GSM780712Trastuzumab treated after 4 days (T3_1)1132.596
GSM780722Trastuzumab treated after 4 days (T1_2)1217.8696
GSM780723Trastuzumab treated after 4 days (T2_2)1036.6596
GSM780724Trastuzumab treated after 4 days (T3_2)1121.3296
GSM780713Pertuzumab treated after 4 days (P1_1)1243.6296
GSM780714Pertuzumab treated after 4 days (P2_1)1248.0396
GSM780715Pertuzumab treated after 4 days (P3_1)1175.196
GSM780725Pertuzumab treated after 4 days (P1_2)1353.5797
GSM780726Pertuzumab treated after 4 days (P2_2)1082.3796
GSM780727Pertuzumab treated after 4 days (P3_2)1202.3196
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)938.96395
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)1371.8797
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)984.34195
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)1081.2296
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)1214.6396